What Is Pluvicto?

Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as ¹⁷⁷Lu-PSMA-617) is an FDA-approved targeted radioligand therapy. It combines two parts:

  • A targeting molecule — a small ligand that binds to prostate-specific membrane antigen (PSMA), a protein present on the surface of most prostate cancer cells.
  • A radioactive payload — lutetium-177, a beta-emitter that delivers therapeutic radiation over a very short distance (about 2 mm).

When Pluvicto is infused, the ligand seeks out PSMA-expressing prostate cancer cells anywhere in the body, attaches to them, and releases its radiation directly inside or right next to the tumor — sparing most normal tissue.

FDA-Approved Indication

Pluvicto is approved for adult men with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with both an androgen receptor pathway inhibitor (e.g., abiraterone or enzalutamide) and taxane-based chemotherapy (such as docetaxel).

How Pluvicto Works

Step 1: Confirm PSMA Positivity

  • Before Pluvicto, you undergo a PSMA PET-CT scan using a diagnostic radiotracer (e.g., gallium-68 PSMA-11 or piflufolastat F-18)
  • The scan confirms that your cancer cells express PSMA — the molecular target Pluvicto needs to work
  • Patients without sufficient PSMA expression are not candidates

Step 2: Targeted Therapy

  • Pluvicto is given as an IV infusion at a specialized facility
  • The radioligand circulates and binds to PSMA on cancer cells
  • Lutetium-177 emits beta radiation that damages the cancer cell DNA
  • Cells without PSMA receive minimal radiation — sparing normal tissue

Treatment Schedule

Pluvicto is given every 6 weeks, for up to 6 doses total (about 8–9 months of treatment if you receive the full course). Each visit is outpatient.

Who Is a Candidate?

Ideal Candidates

  • Metastatic castration-resistant prostate cancer
  • PSMA-positive on diagnostic PET-CT scan
  • Prior treatment with at least one AR-pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide)
  • Prior taxane chemotherapy (docetaxel and/or cabazitaxel)
  • Adequate bone marrow, kidney, and liver function

May Not Be Ideal For

  • PSMA-negative or weakly PSMA-expressing disease
  • Significant bone marrow suppression
  • Severe kidney impairment
  • Active urinary obstruction (must be relieved first)
  • Inability to follow brief radiation-safety precautions at home

As more data emerges, Pluvicto is being studied earlier in the disease course (before chemotherapy, and even before castration-resistance). We work with your medical oncologist to time it appropriately and to consider clinical trials when relevant.

What Are the Results?

FDA approval was based on the landmark VISION trial, which randomized 831 men with PSMA-positive mCRPC who had progressed on AR-pathway inhibitors and taxane chemotherapy.

Outcome Result vs. Standard Care Alone
Overall survival 15.3 vs. 11.3 months (~38% reduction in risk of death)
Radiographic progression-free survival 8.7 vs. 3.4 months
PSA decline ≥50% ~46% of patients
Pain and quality of life Improved across multiple domains

Side Effects

Common (≥20%)

  • Fatigue
  • Dry mouth (the salivary glands also express PSMA)
  • Nausea
  • Decreased appetite
  • Constipation
  • Anemia

Less Common but Important

  • Low platelet or white blood cell counts
  • Kidney injury (especially with dehydration)
  • Dry eyes
  • Tumor-related pain "flare" in the first cycle
  • Risk of secondary cancers from radiation (small, long-term)

Routine bloodwork is performed before each cycle to monitor blood counts and kidney function.

Radiation Safety After Treatment

Pluvicto delivers therapeutic radiation, so simple precautions are needed for a short time after each infusion to protect family members and others around you. Most precautions are needed for the first 2–3 days, with reduced steps continuing for about 1 week.

First 2–3 Days

  • Drink plenty of fluids and urinate frequently to clear the radiotracer
  • Sit down to urinate; flush the toilet twice and wash hands well
  • Sleep alone if possible; otherwise maintain ~6 feet from your partner
  • Limit close contact with children and pregnant women
  • Wash any soiled clothing or linens separately

Days 4–7

  • Most precautions can ease
  • Continue good hand hygiene and toilet flushing habits
  • Limit prolonged close contact with pregnant women and very young children for the first week
  • Resume normal activity as guided by your team

You will receive detailed written instructions and a wallet card noting your treatment in case of routine medical encounters.

What to Expect During Treatment

Before Each Cycle

  • Bloodwork (CBC, kidney/liver tests)
  • Symptom review with your team
  • Hydration encouraged the day before

Infusion Day

  • Pre-infusion vital signs and IV placement
  • Pluvicto is administered over ~30 minutes
  • Brief observation, then home the same day
  • You receive radiation-safety instructions before leaving

Between Cycles

  • 6-week interval before the next dose
  • Continue testosterone-lowering therapy unless directed otherwise
  • Regular labs and imaging to track response

Total treatment course: up to 6 doses over approximately 8–9 months.

Frequently Asked Questions

Is Pluvicto a cure?

No. Pluvicto is a life-extending therapy for advanced prostate cancer. It can shrink tumors, improve symptoms, and lengthen survival, but it does not cure the disease. We use it as one piece of a longer treatment plan.

Why do I need a PSMA PET-CT scan first?

Pluvicto only works if your cancer expresses PSMA. The PET-CT scan confirms PSMA expression and helps identify all sites of disease. Without enough PSMA on the cancer, the therapy cannot find its target.

Will I be radioactive after the infusion?

For a short time, yes — at very low levels. The simple radiation-safety steps above are sufficient. Most patients can return to most daily activities within 24–48 hours.

Can I take Pluvicto with other prostate-cancer therapies?

Pluvicto is given alongside testosterone-lowering therapy. The decision to combine it with other agents (e.g., bone-targeted therapy, AR-pathway inhibitors, or chemotherapy) depends on your specific situation and is made with your medical oncologist.

Is Pluvicto covered by insurance?

Yes. Pluvicto is covered by Medicare and most private insurance plans for FDA-approved indications. Our team handles prior authorization and confirms coverage before treatment begins.

Targeted Therapy Where Other Treatments Have Stopped Working

For men with advanced PSMA-positive prostate cancer who have progressed through earlier therapies, Pluvicto offers a precision-targeted approach with meaningful survival and symptom benefits. Our team coordinates the PSMA PET-CT scan, prior authorization, and treatment scheduling end-to-end.

  • ✅ PSMA PET-CT eligibility confirmation
  • ✅ Up to 6 outpatient infusions, every 6 weeks
  • ✅ Coordinated with hormonal and chemotherapy plans
  • ✅ Insurance verification and authorization handled by our team
Schedule Your Consultation

Call 678-344-8900 to speak with our advanced-prostate-cancer team